Genomix Thera
Genomix Thera, established in 2016 by Dr. Maximilian Fischer, is at the forefront of precision oncology, integrating CRISPR-Cas9 gene editing with quantum-guided nanoparticle delivery systems. The company focuses on personalized cancer therapies that target genomic alterations and modulate epigenetic factors, enhancing immune responses and addressing the tumor microenvironment. With successful Phase I trials for CRISPR-Nanobot therapy and an international patent for their AI-driven immunotherapy optimization algorithm, Genomix Thera is expanding its research facilities in Europe, positioning itself as a leader in the evolving landscape of cancer treatment.
Genomix Thera
Genomix Thera, established in 2016 by Dr. Maximilian Fischer, is at the forefront of precision oncology, integrating CRISPR-Cas9 gene editing with quantum-guided nanoparticle delivery systems. The company focuses on personalized cancer therapies that target genomic alterations and modulate epigenetic factors, enhancing immune responses and addressing the tumor microenvironment. With successful Phase I trials for CRISPR-Nanobot therapy and an international patent for their AI-driven immunotherapy optimization algorithm, Genomix Thera is expanding its research facilities in Europe, positioning itself as a leader in the evolving landscape of cancer treatment.